Cargando…

Sodium–glucose cotransporter 2 inhibitor‐induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score‐matched model analysis in Japan

AIMS/INTRODUCTION: Large‐scale clinical trials have reported that, in patients with type 2 diabetes mellitus, sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment affords favorable renal outcomes; the underlying mechanisms, however, remain unclear. Thus, this study investigated how SGLT2 inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Kazuo, Toyoda, Masao, Hatori, Nobuo, Furuki, Takayuki, Sakai, Hiroyuki, Sato, Kazuyoshi, Miyakawa, Masaaki, Tamura, Kouichi, Kanamori, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354503/ https://www.ncbi.nlm.nih.gov/pubmed/33377605 http://dx.doi.org/10.1111/jdi.13491

Ejemplares similares

Polypharmacy influences the renal composite outcome in patients treated with sodium‐glucose cotransporter 2 inhibitors
por: Kobayashi, Kazuo, et al.
Publicado: (2022)

Concomitant treatment with insulin and sodium–glucose cotransporter 2 inhibitors was associated with the renal composite outcome in Japanese patients with type 2 diabetes and chronic kidney disease: A propensity score‐matched analysis
por: Toyoda, Masao, et al.
Publicado: (2022)

Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
por: Kobayashi, Kazuo, et al.
Publicado: (2022)

The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
por: Kobayashi, Kazuo, et al.
Publicado: (2021)

Blood pressure after treatment with sodium–glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score‐matched models
por: Kobayashi, Kazuo, et al.
Publicado: (2020)

Comparison of questionnaire responses regarding awareness of Japanese Society of Hypertension guidelines for the management of hypertension between 2014 and 2019 in primary care
por: Kobayashi, Kazuo, et al.
Publicado: (2021)

Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease
por: Kobayashi, Kazuo, et al.
Publicado: (2019)

The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists
por: Kobayashi, Kazuo, et al.
Publicado: (2023)

Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes
por: Yoshimoto, Takuo, et al.
Publicado: (2017)

Primary Care-Based Investigation of the Effect of Sitagliptin on Blood Pressure in Hypertensive Patients With Type 2 Diabetes
por: Yuasa, Shouhei, et al.
Publicado: (2017)

Impact of the first announced state of emergency owing to coronavirus disease 2019 on stress and blood pressure levels among patients with type 2 diabetes mellitus in Japan
por: Ito, Shun, et al.
Publicado: (2022)

Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong
por: Mui, Jonathan V., et al.
Publicado: (2023)

Real‐world risk of lower‐limb amputation associated with sodium–glucose cotransporter 2 inhibitors versus metformin: A propensity score‐matched model analysis in Japan
por: Mizutani, Gen, et al.
Publicado: (2022)

Impact of early initiation of sodium-glucose cotransporter 2 inhibitor on cardiovascular outcomes in people with diabetes and known or at risk of atherosclerotic cardiovascular disease: Propensity score matched analysis
por: Sun, Wen, et al.
Publicado: (2022)

Influence of stress induced by the first announced state of emergency due to coronavirus disease 2019 on outpatient blood pressure management in Japan
por: Kobayashi, Kazuo, et al.
Publicado: (2021)

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
por: Arai, Taeang, et al.
Publicado: (2021)

Real‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan
por: Horii, Takeshi, et al.
Publicado: (2023)

Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study
por: Chang, Ting-Yung, et al.
Publicado: (2022)

The Proportion of Long-term Response to Anti-N IgG Antibody after 12 Months for COVID-19 Subclinical Infections and a Longitudinal Survey for COVID-19 Subclinical Infections in 2021
por: Matsuba, Ikuro, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema
por: Takatsuna, Yoko, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
por: Mui, Jonathan V., et al.
Publicado: (2021)

Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
por: Lee, Sharen, et al.
Publicado: (2022)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Sodium‐glucose cotransporter‐2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity‐score‐matched, new‐user design study with an active comparator using the IQVIA Medical Research Data UK database
por: Subramanian, Anuradhaa, et al.
Publicado: (2022)

Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes
por: Kawasoe, Shin, et al.
Publicado: (2017)

A Prospective, Open-Label Short-Term Pilot Study on Modification of the Skin Hydration Status During Treatment With a Sodium-Glucose Cotransporter-2 Inhibitor
por: Tezuka, Yuji, et al.
Publicado: (2020)

Sodium–glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice
por: Murashima, Miho, et al.
Publicado: (2021)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor
por: Miyauchi, Masaaki, et al.
Publicado: (2017)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Yang, Fan, et al.
Publicado: (2020)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
por: Sun, He, et al.
Publicado: (2023)

Sodium–glucose cotransporter-2 inhibitors in patients without diabetes
por: Fryml, Elise, et al.
Publicado: (2023)

Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies
por: Austin, Peter C
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9e21f1u1f54m4fe8pmdoforj2g